BusinessHealthcareIndustriesSci-TechUncategorized

Immuno-oncology Drugs Market 2019 Industry Trends, Sales, Supply, Demand, Analysis & Forecasts to 2025

Press Release

WiseGuyRerports.com Presents “Global Immuno-oncology Drugs Market Insights, Forecast to 2025” New Document to its Studies Database

The global Immuno-oncology Drugs market is valued at 49200 million US$ in 2018 and will reach 142200 million US$ by the end of 2025, growing at a CAGR of 14.2% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Immuno-oncology Drugs market based on company, product type, end user and key regions.

This report studies the global market size of Immuno-oncology Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Immuno-oncology Drugs in these regions.
This research report categorizes the global Immuno-oncology Drugs market by top players/brands, region, type and end user. This report also studies the global Immuno-oncology Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

Key players:

Amgen, Inc
AstraZeneca, Plc
Bristol-Myers Squibb
Celgene Corporation
Eli Lilly and Company
Merck & Co.
Hoffmann-La Roche AG
Johnson & Johnson
Novartis International AG
AbbVie, Inc.
Pfizer Inc.
Sanofi S.A.
EMD Serono, Inc.
Gilead Sciences Inc.
Prometheus Therapeutics & Diagnostics
Aduro BioTech
Galena Biopharma
Bavarian Nordic
Celldex Therapeutics
ImmunoCellular Therapeutics
Incyte

Request Free Sample Report @ https://www.wiseguyreports.com/sample-request/4189847-global-immuno-oncology-drugs-market-insights-forecast-to-2025

 

The report found on Immuno-oncology Drugs analyses the Immuno-oncology Drugs market and offers a comprehensive understanding of all its related aspects which are likely to influence its growth. The report overview comprises of the Immuno-oncology Drugs market’s scope and insightful information on the Immuno-oncology Drugs market drivers and restraints, trends, growth opportunities, and market size and shares. The report details every Immuno-oncology Drugs market parameters that are likely to impact its growth and also states the parameter’s short-term, medium-term, and long-term impression on the market.

An exhaustive primary and secondary research of the Immuno-oncology Drugs market that has been undertaken by expert analysts assist in deriving a clear outlook of the Immuno-oncology Drugs market values and its prospects. A bottom-up approach has been employed to calculate the Immuno-oncology Drugs market revenue generation and predict the final valuation and CAGR that is likely to be attained over the forecast period of 2019 to 2025.

 

Complete Report Details @ https://www.wiseguyreports.com/reports/4189847-global-immuno-oncology-drugs-market-insights-forecast-to-2025

 

Table Of Contents:     

1 Study Coverage
1.1 Immuno-oncology Drugs Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Immuno-oncology Drugs Market Size Growth Rate by Product
1.4.2 Immune Checkpoint Inhibitors
1.4.3 Monoclonal Antibodies
1.4.4 Cytokine-Based Immunotherapy
1.4.5 Cancer Vaccines
1.4.6 CAR-T Cell Therapy
1.5 Market by End User
1.5.1 Global Immuno-oncology Drugs Market Size Growth Rate by End User
1.5.2 Hospitals
1.5.3 Pharmacies
1.5.4 Online Pharmacies
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Immuno-oncology Drugs Market Size
2.1.1 Global Immuno-oncology Drugs Revenue 2014-2025
2.1.2 Global Immuno-oncology Drugs Sales 2014-2025
2.2 Immuno-oncology Drugs Growth Rate by Regions
2.2.1 Global Immuno-oncology Drugs Sales by Regions
2.2.2 Global Immuno-oncology Drugs Revenue by Regions

11 Company Profiles
11.1 Amgen, Inc
11.1.1 Amgen, Inc Company Details
11.1.2 Company Business Overview
11.1.3 Amgen, Inc Immuno-oncology Drugs Sales, Revenue and Gross Margin (2014-2019)
11.1.4 Amgen, Inc Immuno-oncology Drugs Products Offered
11.1.5 Amgen, Inc Recent Development
11.2 AstraZeneca, Plc
11.2.1 AstraZeneca, Plc Company Details
11.2.2 Company Business Overview
11.2.3 AstraZeneca, Plc Immuno-oncology Drugs Sales, Revenue and Gross Margin (2014-2019)
11.2.4 AstraZeneca, Plc Immuno-oncology Drugs Products Offered
11.2.5 AstraZeneca, Plc Recent Development
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Company Details
11.3.2 Company Business Overview
11.3.3 Bristol-Myers Squibb Immuno-oncology Drugs Sales, Revenue and Gross Margin (2014-2019)
11.3.4 Bristol-Myers Squibb Immuno-oncology Drugs Products Offered
11.3.5 Bristol-Myers Squibb Recent Development
11.4 Celgene Corporation
11.4.1 Celgene Corporation Company Details
11.4.2 Company Business Overview
11.4.3 Celgene Corporation Immuno-oncology Drugs Sales, Revenue and Gross Margin (2014-2019)
11.4.4 Celgene Corporation Immuno-oncology Drugs Products Offered
11.4.5 Celgene Corporation Recent Development
11.5 Eli Lilly and Company
11.5.1 Eli Lilly and Company Company Details
11.5.2 Company Business Overview
11.5.3 Eli Lilly and Company Immuno-oncology Drugs Sales, Revenue and Gross Margin (2014-2019)
11.5.4 Eli Lilly and Company Immuno-oncology Drugs Products Offered
11.5.5 Eli Lilly and Company Recent Development

 

CONTACT US:

NORAH TRENT

Partner Relations & Marketing Manager

[email protected]

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Tags

Related Articles

Close